Dr. Ahmad Trad

Developing a site-selective orientated immobilization of antibody and antibody fragments (e.g. Fab, scFv) to the IR sensor Discovery of new monoclonal antibodies against misfolded proteins related to different neurodegenerative disorders

• Managed and leaded a team, including education, coaching and training • Prepared and presented data on internal and external meetings • Supervised of technology transfer of processes to the cell culture • Generated stable cell lines (from e.g. CHO, HEK cell lines) • Designed and performed cell-based assays • Sorted antigen specific B cells • Engineered transgenic animals • Constructed antibody libraries from immunized animals • Screened antibodies using High-Throughput devices

• Validation of ADAM17 as potential target for immunotherapy • Construction of bispecific T-cell engager antibody (BiTE) • In vitro testing of BiTE • Generation of monoclonal antibodies against different antigens • Characterization and validation of monoclonal antibodies for different immunological assays (e.g. FACS, WB, IP) • Development of sandwich ELISA to quantify ADAM17, UCH-L1, NOD2 and meprin α • Establishment of ELISA to detect Cercospora beticola

• Investigation of the immune response of transgenic mice harbored only one single DH gene in their genome instead of 13 DH genes as in BALB/c wild-type mice using 2-phenyloxazolone (phox) as model antigen • Analysis of the immune response (Titer, B and T cells) • Generation of monoclonal antibodies against phox • Sequencing of monoclonal antibodies • Affinity measurement by SPR and competitive ELISA • Bioinformatic analysis of VH/VL genes